Wnt signaling follows canonical and non-canonical pathways to regulate a variety of processes during cellular homeostasis and development. The large T-antigen (T-Ag) of the human neurotropic JC virus, has been shown to modulate the Wnt-signaling pathway via interaction with b-catenin, one of the most important components of the canonical Wnt pathway. Here, we have identified an alternative non-canonical pathway that allows T-Ag to recruit Rac1 for stabilizing b-catenin by inhibiting its ubiquitin-dependent proteasomal degradation. We demonstrate that inhibition of Rac1 by its dominant negative mutant, RacN17, abrogates T-Ag-mediated stabilization of b-catenin yet exhibits no impact on the transcriptional activity of b-catenin. Results from immunocytochemistry revealed that together with T-Ag, a pool of b-catenin appears at the cell surface, particularly at the membrane ruffles where active Rac1 is positioned. Interestingly, cooperativity between T-Ag and b-catenin leads to activation of Rac1, which in turn, stimulates its association with b-catenin. These observations unravel the interplay between b-catenin and Rac1 that is initiated by T-Ag and results in stabilization of b-catenin and its presence in cell membrane ruffles.
Introduction b-Catenin is a critical component of two important signaling pathways that regulates cell growth, cell transformation, cell shape and cancer. First, b-catenin is a major component of cell-cell adhesion and links members of adhesion components, such as cadherin, to the actin cytoskeleton (Bienz and Clevers, 2000) . Secondly, b-catenin acts as a key effector of Wnt-signaling pathway to promote cell growth, differentiation and gene expression (Nusse, 2005) . Other than the classical b-catenin-mediated canonical pathway, Wnt signaling also regulates Ras homology (Rho) GTPases (Rho, Rac and cdk42) (Malliri and Collard, 2003) . Increasing evidence suggests a regulating role for Rho GTPases in cadherin and b-catenin families (Wildenberg et al., 2006) . Mutations in Rac GTPases have also been found in many human brain tumors (Hwang et al., 2005) .
Large T-antigen (T-Ag) of the neurotropic polyomavirus (JC virus, JCV) has been found to transform cells of neuronal origin, and its expression in experimental animal induces development of various neuronal origin tumors, including medulloblastoma (White et al., 2005) . T-Ag of JCV has been shown to interact with one of the most important constituents of Wnt-signaling pathway, b-catenin (Gan and Khalili, 2004 ). Here we suggest that JCV T-Ag stabilizes b-catenin by inhibiting b-catenin proteasomal degradation, which can be blocked by inhibiting Rac1, but not glycogen synthase kinase (GSK)-3b. We demonstrate that T-Ag promotes Rac1 in the presence of b-catenin and facilitates b-catenin association with active Rac1 at the cell surface. These results ascribe a new role for Rac1 in T-Ag-mediated b-catenin stabilization.
Results

T-Ag enhances b-catenin expression level by inhibiting its ubiquitin-dependent proteasomal degradation
As the stabilization of b-catenin in the Wnt-signaling pathway is largely regulated by ubiquitination-dependent proteasomal degradation, we compared the level of b-catenin degradation in the absence or presence of T-Ag. In accord with our earlier report (Gan and Khalili, 2004) , the level of b-catenin increased in cells expressing T-Ag ( Figure 1a , lanes 1 and 2). In the absence of T-Ag, treatment of cells with the proteasomal inhibitor, acetyle-L-leucyl-L-norleucinal (ALLN), increased the level of b-catenin (Figure 1a , compare lanes 1 and 3), whereas in the presence of T-Ag, this treatment had no effect on the level of b-catenin (Figure 1a , compare lanes 2 and 4) suggesting that T-Ag may stabilize b-catenin by inhibiting its proteasomal degradation. The level of housekeeping protein, Grb2, remained unchanged (data not shown). Since proteasomal degradation of b-catenin may require its ubiquitination (Aberle et al., 1997) , protein extracts from cells expressing myc-epitope-tagged b-catenin, in the absence or presence of T-Ag, were used in immunoprecipitation (IP) with anti-myc antibody that recognizes myc-tagged bcatenin and immunoblotted with anti-ubiquitin (Ub) antibody to specifically detect ubiquitinated b-catenin. Cells that overexpressed b-catenin alone showed a more intense ladder of ubiquitinated protein compared to that from cells overexpressing b-catenin plus T-Ag ( Figure 1a , compare lanes 5 and 6). The differences in intensity between the ubiquitinated proteins from the cell lysates expressing b-catenin, with or without T-Ag, were more pronounced upon treatment with ALLN ( Figure 1a , compare lanes 7 and 8). As expected, no ubiquitinated complexes were detected in untreated control or ALLN-treated cells transfected with empty vector (not shown). These observations verified that T-Ag stabilizes b-catenin by partially inhibiting its ubiquitination and hence, prevents its proteasomal degradation.
Next, we compared the effect of the proteasomal inhibitor (ALLN) on full-length b-catenin and its DN (D1-132) mutant in the absence or presence of T-Ag. The level of T-Ag-induced full-length b-catenin was greater than that of DNb-catenin (Figure 1b , compare lanes 1 and 2 with 5 and 6). Treatment of T-Ag-expressing cells with ALLN failed to further increase the level of full-length b-catenin and the DNb-catenin (Figure 1b , compare lanes 2 and 4, and lanes 6 and 8). In the absence of T-Ag, ALLN treatment, which elevated the level of full-length b-catenin (Figure 1b, lanes 1 and 3) , showed no increase on the level of DNb-catenin (Figure 1b, lanes 5 and 7) . In light of earlier results on the ability of both full-length b-catenin and DNbcatenin mutant in binding to T-Ag (Gan and Khalili, 2004) , these observations suggest that T-Ag may stabilize b-catenin by an alternative pathway, that is, inhibition of proteasomal degradation, which appear to be independent from T-Ag interaction.
GSK-3b phosphorylates the specific residues at the N terminus of b-catenin and facilitates its ubiquitination and proteasomal degradation (Kikuchi et al., 2006) . Thus, in the next study, we examined the level of GSK-3b involvement in T-Ag-mediated stabilization of b-catenin. Cells transfected with plasmids expressing myc-b-catenin, T-Ag, and HA-GSK-3b were subjected to the TOPFLASH transcription reporter assay, which is used as a reporter for b-catenin activity, in presence or absence of lithium chloride (LiCl), a widely used inhibitor of GSK-3b (Bachar-Dahan et al., 2006) . As expected, the LiCl treatment promoted a nearly twofold Results from TOPFLASH transcription assays revealed that RacN17, and to a lesser degree Rho19, have only a minor effect on the activity of b-catenin ( Figure 2b ). These observations indicate that the effect of T-Ag on the stability of b-catenin requires Rac1 and that this event may only be partially involved in T-Agmediated b-catenin transcription activity.
Next, we investigated the steady-state level of b-catenin after treatment of cells with cycloheximide. Cells were transfected with plasmids expressing b-catenin, T-Ag and RacN17, in various combinations. Results from western blot analysis indicated a significant decrease in the level of b-catenin at 2 and 5 h after treatment of cells expressing T-Ag and RacN17 compared to those expressing only T-Ag (Figure 3a , compare lanes 4-6 with lanes 7-9). The apparent half-life of b-catenin, as determined by densitometry, in the presence of empty vector and T-Ag was approximately 5 h, and in the presence of RacN17, was less than 2 h (data not shown). The decline in the stability of b-catenin was observed in spite of gradual degradation of RacN17 after cycloheximide treatment (Figure 3a , lower panel, compare lane 7 to lanes 8 and 9). Once again, these results highlight the role of Rac1 in T-Ag-mediated stabilization of b-catenin as evidenced by the ability of the dominant negative mutant of Rac1 in reducing the half-life of b-catenin.
Examination of the effect of RacN17 on T-Ag-mediated stabilization of full-length b-catenin and its DN mutant revealed that in contrast to full-length b-catenin, the level of DNb-catenin remained unchanged in the presence of RacN17 (Figure 3b , compare lanes 1-3 to lanes 4-6). The level of housekeeping protein, Grb2, served as an internal control for protein loading. The presence of T-Ag and RacN17 in relevant transfected cells was verified by western blot analysis (Figure 3c ). These results suggest that the interaction of T-Ag and b-catenin is required for Rac1 to exert its effect on b-catenin stabilization by T-Ag.
Subcellular localization of b-catenin
The subcellular localization of b-catenin plays an important role in its stability and function (Nusse, 2005) . Overproduction of full-length and DNb-catenin (b) Equal amount of the lysates were subjected to luciferase assay and the activities were normalized by measuring b-galactosidase activity. Results were expressed as fold activity with respect to the control, and the mean7s.e.m. were calculated based on triplicate experiments.
Role of Rac1 in b-catenin stabilizationled to their accumulation in the cytoplasm as well as in the nucleus of the cells (Figures 4a and b) . Interestingly, in the presence of T-Ag, full-length b-catenin was also detected at the cell surface and membrane ruffles along with cytoplasmic and some nuclear staining (Figure 4d, arrowheads) . In response to T-Ag expression, DNb-catenin retained its intense nuclear and cytoplasmic presence, and showed no cell surface or membrane ruffle distribution (Figure 4c) . Expression of RacN17 completely abrogated the cell-surface distribution of b-catenin, but not its cytoplasmic and nuclear positions (Figure 4e ). This observation is in accord with results from transcription assay (Figure 2b ) where RacN17 showed no major impact on T-Ag-induced b-catenin gene transcription, in spite of its inhibitory effect on T-Ag-induced stabilization of b-catenin (Figure 3b) .
Next, we performed subcellular fractionation of cells expressing T-Ag, and RacN17, in various combinations, and determined the level of b-catenin by immunoblot assay. Since the level of b-catenin is varied in the absence or presence of T-Ag and/or T-Ag and RacN17, first, we normalized b-catenin expression level by adjusting the amount of b-catenin expression plasmid DNA used in the transfection (Figure 4f ). To perform Role of Rac1 in b-catenin stabilizationsubcellular fractionation, the level of b-catenin expression was kept comparable by selecting an appropriate DNA concentration based on Figure 4f . Total (T) protein extracts from the transfected cells were fractionated into membrane rich (M) and cytoplasmic (C) fractions, and the result demonstrated that b-catenin is mainly distributed in the cytoplasmic fraction when expressed alone. b-catenin partitioning to the membrane fraction was observed in cells expressing T-Ag (Figure 4g , compare lanes 4 and 5). A minor decrease in the cytoplasmic level of b-catenin was also noted in the presence of T-Ag (Figure 4g , compare lanes 7 and 8). As expected, coexpression of RacN17 abrogated cellsurface distribution of b-catenin (compare lanes 5 and 6), although its levels remained virtually unchanged in the cytoplasmic fraction. The lysates were also immunoblotted with anti-T-Ag and anti-HA antibodies to verify expression of T-Ag and HA-epitope-tagged RacN17, respectively (data not shown). Thus, the data support our immunofluorescence observations and further indicate that, in the presence of T-Ag, b-catenin associates with the cell surface in a Rac1-dependent manner leading to b-catenin stabilization.
We also tested the distribution of T-Ag and b-catenin in the presence of HA-epitope-tagged RacN17. As seen in Figure 5a small fraction of T-Ag was detected at the cell surface of the cells transfected with plasmids for T-Ag, T-Ag plus b-catenin and T-Ag plus b-catenin and RacN17 (a-c, respectively). As expected, the majority of T-Ag was found in the nucleus with some cytoplasmic appearance. Immunostaining of the cells for b-catenin showed codistribution of b-catenin at the cell surface of cells expressing T-Ag (Figures 5, compare b and e) . In contrast, b-catenin was predominantly cytoplasmic when expressed alone or with T-Ag and RacN17 (Figures 5d and f, respectively) . These data support our previous observations and further demonstrate that a pool of cell surface-associated T-Ag is able to colocalize with b-catenin in a Rac1-dependent manner.
To confirm the immunofluorescence, we performed fractionation analysis. As shown in Figure 5 , T-Ag was present in the membrane fractions as well as in the cytoplasmic fractions when expressed with control plasmid or with b-catenin (lanes 5 and 8). In the presence of RacN17, only a small amount of T-Ag is partitioned into the membrane fraction (Figure 5g , lane 6) suggesting that the dominant negative Rac has an effect on cell-surface distribution of T-Ag.
T-Ag and b-catenin-induced Rac1 activation As T-Ag and b-catenin, by stimulating Rac1, may develop a positive feedback loop that allows T-Ag to enhance b-catenin stability at the cell surface, in the next study we assessed the ability of T-Ag and b-catenin to promote Rac activity. We employed serum response Role of Rac1 in b-catenin stabilization R Bhattacharyya et al element (SRE)-luciferase assay, which is often used to determine Rho-signaling pathway (Mao et al., 1998) , in cells expressing T-Ag, b-catenin and various mutants of Rac1 and RhoA. As shown in Figure 5a , SRE activity was enhanced (three-to fourfold) in cells expressing T-Ag or b-catenin. Coexpression of the two proteins had a synergistic effect on SRE activity and caused a nearly 15-fold induction. Interestingly, the enhanced SRE activity was severely suppressed in the presence of RacN17 but not RhoN19. In light of earlier reports on the localization of active Rac1 in membrane and membrane ruffles (Michaelson et al., 2001) , and our data pointing to the involvement of Rac1 in b-catenin stabilization by T-Ag, we tested the ability of b-catenin to interact with Rac1 in the absence and presence of T-Ag. Results from immunoblot analysis of the complexes containing b-catenin showed a weak detection of b-catenin in HA-Rac-associated complex in the presence of T-Ag (Figure 6b ). The binding was enhanced when a constitutively active mutant RacV12 was coexpressed with T-Ag. Altogether, these data suggest that while T-Ag promotes Rac activation, it also facilitates b-catenin association with active Rac 1, most likely at the cell surface, as RacV12 is primarily cell-surface associated.
Discussion
Aberrant Ub-proteasome-dependent degradation of critical signaling components is found to play a key oncogenic force underlying tumorigenesis of tumor viruses (Shackelford and Pagano, 2004) . Here we identify a novel pathway by which T-Ag of JCV can modulate b-catenin levels and its subcellular localization via Rac1 activation. Investigation on cells from T-Aginduced tumors in animal models and several clinical samples has led to the identification of multiple pathways including p53, pRb, IRS, NF1/NF2 and b-catenin, which may be dysregulated by T-Ag (Khalili et al., 2006) . Here we show that T-Ag can recruit Rac1 to stabilize b-catenin levels and enhance its localization in the cell-surface membrane where active Rac1 is usually located and operational (Akiyama and Kawasaki, 2006) . While our results point out that T-Ag interaction with b-catenin may not be sufficient in this pathway, the detection of T-Ag at the cell surface along with b-catenin suggests the importance of T-Ag and b-catenin presence and possibly their functional cooperativity at the site of the membrane. In fact, our results indicate that T-Ag and b-catenin synergistically activate According to one model, by localizing b-catenin at the cell surface, T-Ag promotes Rac1 activation, which in turn, facilitates its association with active Rac1 and spatially dissociates b-catenin from proteasomal degradation. In support of this notion, active RacV12 was shown to associate with the cell surface in many cells (Michaelson et al., 2001) , and dominant negative RacN17 abrogated cell-surface association as well as stabilization of b-catenin in T-Ag-expressing cells. Figure 7 illustrates a model in which T-Ag can modulate b-catenin via a GSK-3b-dependent and GSK-3b-independent pathway that involves Rac1. Whether or not both pathways can be simultaneously operative or their function is determined by the stage or type of the cells remains to be investigated. In general, T-Ag of JCV is found predominantly in the nucleus; however, we were able to detect a pool of T-Ag at the cell surface that colocalized with b-catenin. This is in accord with other observations where JCV T-Ag was reported to interact with a variety of membrane-associated proteins such as NF2 or IRS-1 (Shollar et al., 2004) . Accordingly, a close relative of JCV T-Ag, the SV40 T-Ag was also demonstrated to associate with the membrane (Butel et al., 1989) . Recently, the association of ubiquitinating enzymes between SV40 T-Ag (Welcker and Clurman, 2005) as well as between active Rac1 (Senadheera et al., 2001 ) have been reported, providing additional clues on the involvement of T-Ag in ubiquitination pathway that may promote its oncogenic activities.
Materials and methods
Plasmids and reagents pcDNA3/JCVT, pmyc-b-catenin, pDNb-catenin, and pTOP-FLASH-luciferase (luc) have been described previously (Gan and Khalili, 2004) . We constructed pcDNA3HA-RacN17. pcDNA3myc-RhoN19, pcDNA3HA-wtRac1 and pcDNA3-HARacV12 were purchased from UMR cDNA Resource Center, (Rolla, MO, USA). ALLN (Calbiochem, San Diego, CA, USA), lithium chloride (Sigma, St Louis, MO, USA) and cycloheximide (Sigma) were used at concentrations indicated.
Cell fractionation
Equal amounts of lysates were separated into membrane rich (M) and cytoplasmic (C) fractions after high-speed centrifugation, as described elsewhere (Bhattacharyya and Wedegaertner, 2000) . A total of 10 or 30 mg of the fractions from each was used for immunoblotting (IB).
Immunofluorescence assay Immunofluorescence microscopy as described previously (Gan and Khalili, 2004) . Monoclonal mouse antibodies (3 mg/ml) against myc-epitope (Novagen, San Diego, CA, USA) and T-Ag (pAb2; EMD Bioscience, San Diego, CA, USA) were used. Polyclonal antibody (1:200) against myc-epitope Role of Rac1 in b-catenin stabilization(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used for double labeling.
TOPFLASH luciferase gene transcription assay U-87MG cells were used for TOPFLASH and SRE assays as described previously (Bhattacharyya and Wedegaertner, 2000) . LiCl treatment was done for 48 h (Bachar-Dahan et al., 2006) and luciferase activities were determined by measuring luminescence activity. The data were normalized by measuring b-galactosidase activity.
Immunoprecipitation and immunoblot analysis
Cell lysates were either subjected to IP using appropriate antibody or subjected to immunoblotting according to the method described earlier (Gan and Khalili, 2004) . We used anti-T-Ag, anti-myc, anti-myc, anti-HA (HA11; Covance, Berkeley, CA, USA), anti-GFP (BD Bioscience, San Jose, CA, USA) and anti-Ub antibodies (Biosource, Carlsbad, CA, USA).
Abbreviations ALLN, acetyle-L-leucyl-L-norleucinal; DMSO, dimethyl sulfoxide; GSK, glycogen synthase kinase; IB, immunoblotting; IP, immunoprecipitation; LiCl, lithium chloride; Rho, Ras homology; SRE, serum response element; T-Ag, Large T-antigen of JC virus; Ub, ubiquitin.
